About Rezolute
Rezolute is a company based in Denver (United States) founded in 2012 by Nevan Charles Elam and Hoyoung Huh. The company has 59 employees as of June 30, 2024. Rezolute offers products and services including Ersodetug. Rezolute operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
- Headquarter Denver, United States
- Employees 59 as on 30 Jun, 2024
- Founders Nevan Charles Elam, Hoyoung Huh
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rezolute, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$74.41 M (USD)-8.7as on Jun 30, 2025
-
EBITDA
-$79.86 M (USD)-13.46as on Jun 30, 2025
-
Latest Funding Round
$41 M (USD), Post-IPO
Oct 09, 2020
-
Investors
Citadel
& 6 more
-
Employee Count
59
as on Jun 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rezolute
Rezolute is a publicly listed company on the NASDAQ with ticker symbol RZLT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Rezolute
Rezolute offers a comprehensive portfolio of products and services, including Ersodetug.
Drug for treating congenital hyperinsulinism in clinical trials
People of Rezolute
Unlock access to complete
Unlock access to complete
Funding Insights of Rezolute
Investors in Rezolute
Rezolute has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, Handok and Genexine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward North American opportunities.
|
Locked | Locked | Locked | |
|
Investment firm managing opportunistic strategies in equity and credit markets.
|
Locked | Locked | Locked |
Investor details for Rezolute
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rezolute
Investment portfolio details for Rezolute
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rezolute
Detailed financials for Rezolute
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rezolute Comparisons
Peer comparison for Rezolute
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rezolute
Rezolute operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
Detailed competitors of Rezolute
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rezolute
Complete news archive for Rezolute
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rezolute
Rezolute was founded in 2012.
Rezolute is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.
Nevan Charles Elam is the current CEO of Rezolute. They have also founded this company.
As of Jun 30, 2024, the latest employee count at Rezolute is 59.
Rezolute (formerly Antriabio) is a biopharmaceutical company, developing drugs for metabolic and orphan diseases. The lead candidate, RZ358 is an insulin receptor antagonist monoclonal antibody for congenital hyperinsulinism (CHI), has an orphan drug designation(Phase 2). Another molecule, AB101 is a once-weekly injectable basal insulin for diabetes management (in Phase 1). Also developing plasma kallikrein inhibitors (PKI) for diabetic macular edema (DME) hereditary angioedema (HAE). In Dec 2017, the company had entered into a license agreement with Xoma which gives Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358.
Rezolute's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Rezolute offers Ersodetug.
Yes, Rezolute is publicly traded on NASDAQ under the ticker symbol RZLT.
Rezolute has 7 investors. Key investors include Citadel, Handok, Genexine, CAM Capital, and Federated Hermes.
The ticker symbol of Rezolute is RZLT on NASDAQ.